Epoetin alfa and darbepoetin alfa are erythropoiesis-stimulating agents (ESAs), approved for the treatment of anemia (low red blood cells) resulting from chronic kidney disease.
The Dietary Guidelines for Americans recommend consuming less than 2,300 mg of sodium and 2,6003,400 mg potassium per day (USDA 2026)
Published Research Data Quantified findings from peer-reviewed studies on PT-141 (Bremelanotide) amino acid residues in the PT-141 cyclic peptide sequence HPLC-verified purity range across published batch testing Published Research Studies on PT-141 (Bremelanotide) 2008 Bremelanotide: an overview of preclinical CNS effects J Sex Med 2003 PT-141: a melanocortin agonist for the treatment of sexual dysfunction Ann N Y Acad Sci Characterization of PT-141's mechanism of action through melanocortin MC3R/MC4R receptor activation in central nervous system pathways

Additional well-designed, prospective studies are needed to confirm the potential benefit of GLP-1 receptor agonist treatment for patients with advanced CKD or ESKD." For further information: DOI: 10.1001/jamanetworkopen.2022.1169 Keywords: CKD, ESKD, GLP-1 receptor agonist, DPP-4 inhibitors, type 2 diabetes, JAMA Network Open, chronic kidney disease, end-stage kidney disease, National Health Insurance Research Database of Taiwan, MACCE, Mortality rate